Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 516 matches for

OXvax Ltd. is a spin-out company from the University of Oxford focused on developing an advanced next-generation dendritic cell vaccine platform for treating solid tumour cancers.

Exogene Graduates from the BioEscalator

We are delighted to celebrate the graduation of Exogene as it transitions from the BioEscalator to its new home at the Wood Centre for Innovation.

Simon Meier will be joining Oxford Cancer Analytics (OXcan) as Incoming Interim CEO

Simon brings over two decades of strategic leadership and investment expertise across diagnostics, biotech, and digital health innovation.

Dr.Peter Jianrui Liu to step down as CEO of Oxford Cancer Analytics Ltd (OXcan)

Dr. Peter Jianrui Liu, Co-Founder of OXcan, has decided to step down from his role as the Company’s Founding CEO, to pursue other interests. He will remain a significant shareholder in the Company and therefore will retain every interest in the Company’s development and success as an advisor.

Professor Heidi Johansen-Berg joins the BioEscalator Management Board

We are delighted to welcome Professor Heidi Johansen-Berg to our Management Board, an expert in brain imaging and neuroplasticity, and a champion of innovation in the life sciences.

Theolytics appoints experienced medical oncologist Matilde Saggese, MD, as Chief Medical Officer

Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity

PepGen Announces Pricing of $100 Million Public Offering

PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.

Moa and Nufarm announce next phase for their novel mode of action herbicide

First phase completed a year earlier than typical industry timelines

Oxford Cancer Analytics featured in CTV News

In the piece, CEO and co-founder Dr. Peter Jianrui Liu shares how the company is pioneering a non-invasive blood test for the early detection of lung cancer, using proteomics and AI/ML. Oxford Cancer Analytics' technology aims to change the way cancers are diagnosed, detecting disease earlier, cutting costs for health systems, and most importantly, saving lives.

BioEscalator Bulletin - Autumn 2025

Stay informed with the latest BioEscalator updates, tenant and alumni news in the Autumn 2025 edition of the BioEscalator Bulletin.

Omos Biosciences joins the BioEscalator community to tackle cancer earlier

We are delighted to welcome Omos Biosciences as the newest member of the BioEscalator community. The company has ambitious plans to transform cancer prevention by intervening at the pre-cancerous stage.

Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension

Follows successful completion of pre-clinical activities by Alchemab as part of an earlier licensing deal with Eli Lilly and Company for ATLX-1282. Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors.

OMass Therapeutics enters into exclusive collaboration and license agreement with Genentech to develop and commercialise therapies for inflammatory bowel disease

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease. OMass to receive $20M upfront payment, with potential for more than $400M in additional milestone payments, as well as tiered royalties on net sales.

Moa develops groundbreaking category of crop protection; signs partnership deal with Gowan

OXFORD UK: Moa Technology today announces its discovery of chemistries which could become an entirely new category of products to help farmers protect their harvests more safely, sustainably and effectively.

Green is the new gold: Infinitopes awarded gold LEAF accreditation

Infinitopes has achieved the gold standard among the latest awardees for the Laboratory Efficiency Assessment Framework (LEAF), an innovative initiative to improve laboratory efficiency. As the second BioEscalator tenant to earn this accreditation, they follow in the footsteps of 2023/24 winner, Exogene.

Congratulations Alethiomics, the BioEscalator’s most recent graduate

We’re proud to celebrate the graduation of Alethiomics, a University of Oxford spin-out dedicated to developing innovative treatments for blood cancers, as they move from the BioEscalator to their new home at Abingdon Science Park.

Innovate UK awards Icosphere Biomedical Catalyst grant

Icosphere Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Develop Breakthrough Gene Therapy Vector Manufacturing Technology.

Theolytics featured in Innovate UK Case Study: Harnessing the power of cancer-killing viruses

Theolytics has created an extensive proprietary library of oncolytic viruses (viruses that kill cancer cells) to harness their potential to safely target and destroy tumour cells while leaving healthy cells intact.

Innovate UK feature Infinitopes in recent case study

Infinitopes received Innovate UK funding through the Investor Partnership Programme, which was pivotal to building and testing their cutting-edge discovery platform, and the Cancer Therapeutics Programme, to design, prepare and execute its phase I clinical trial, that scientists hope will be practice-changing.

OMass Therapeutics appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.

Load More

Similar stories